This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

Erratum

In the article "Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months" by Annamaria Colao, Rosario Pivonello, Renata S. Auriemma, Mariano Galdiero, Silvia Savastano, Ludovica F. S. Grasso, and Gaetano Lombardi (J Clin Endo Metab 93:3436–3442; 2008), the authors report an error on page 3437 under "Treatment Protocol." The corrected sentence should read: "After 3 months, the dose was increased to 30 mg every 28 d, if GH was above 2.5 µg/liter and IGF-I levels were not normalized (n = 39), was maintained at 20 mg every 28 d if GH levels fell less than 10 µg/liter (n = 20) or was reduced to 10 mg every 28 days if GH levels were less than 1 µg/liter (n = 4)." The authors apologize for this error and any inconvenience to the readers.

This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content